NEW YORK, Nov. 9, 2017 /PRNewswire/ -- Notice is
hereby given that a class action lawsuit has been filed, on behalf
of shareholders of Intercept Pharmaceuticals, Inc. ("Intercept" or
the "Company") (NasdaqGS: ICPT) on behalf of purchasers of
the Company's securities between May 31,
2016 and September 20,
2017, inclusive (the "Class Period").
The investigation focuses on whether Intercept and
certain of its officers and/or directors violated federal
securities laws.
The Complaint alleges that, throughout the Class Period,
Defendants made materially false and misleading statements
regarding the Company's business, operational and compliance
policies. Specifically, Defendants made false and/or misleading
statements and/or failed to disclose that: (i) Ocaliva entailed
undisclosed safety risks, including death, to patients suffering
from PBC; and (ii) as a result of the foregoing, Intercept's public
statements were materially false and misleading at all relevant
times.
On September 12, 2017, Intercept
issued a letter warning physicians against overdosing patients with
Ocaliva, advising them that the drug has been tied to liver
injuries and death among patients suffering from PBC.
As a result, Intercept's share price fell $24.42, or 24.88%, to close at $73.70 on September 21,
2017.
If you wish to serve as lead plaintiff, you must move the Court
no later than November 27,
2017. Any member of the putative class may move
the Court to serve as lead plaintiff through counsel of their
choice, or may choose to do nothing and remain an absent class
member. If you wish to discuss this action, or have any
questions concerning this notice or your rights or interests,
please contact:
Click here for more information:
https://monteverdelaw.com/investigations/securities/ It is free
and there is no cost or obligation to you.
Monteverde & Associates PC is a boutique class action
securities and consumer litigation law firm committed that has
recovered millions of dollars and is committed to protecting
shareholders and consumers from corporate wrongdoing.
Monteverde & Associates PC lawyers have significant experience
litigating Mergers & Acquisitions and Securities Class Actions,
whereby they protect investors by recovering money and remedying
corporate misconduct.
Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave, Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
Attorney Advertising. (C) 2017 Monteverde & Associates
PC. Prior results do not guarantee a similar outcome with
respect to any future matter.
View original content with
multimedia:http://www.prnewswire.com/news-releases/november-27-2017-lead-plaintiff-deadline-alert-monteverde--associates-pc-encourages-investors-who-suffered-significant-losses-in-intercept-pharmaceuticals-inc-to-contact-the-firm--icpt-300554253.html
SOURCE Monteverde & Associates PC